PULM PULM
Company Profile ↓Company Overview
PULM (PULM) is a publicly traded company listed on with a market capitalization of $6.03M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -69.50% |
| 6 Months: | -36.54% |
| 3 Months: | +21.32% |
| 1 Month: | -4.62% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)49.06 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 69.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.82M | 1.41M | 2.76M | 3.50M | 4.37M | 1.39M | 2.25M | 1.07M | 1.16M | 1.33M | 1.87M | 1.50M | 1.84M | 1.75M | 5.88M | 1.55M | 366.00K | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.85M | 1.55M | 866.00K | 908.00K | 1.29M |
| Operating Income | -2.45M | -2.59M | -1.72M | -2.75M | -11.32M | -4.66M | -5.44M | -8.97M | -3.00M | -3.31M | -5.43M | -4.30M | -5.11M | -6.13M | -4.83M | -5.11M | -4.96M | -7.95M | -3.68M | -4.74M | -1.17M | -1.28M | -4.08M | -3.85M | -8.19M | -4.96M | -4.56M | -5.10M | -4.58M | -3.99M | -3.94M | 747.00K | -5.90M | -2.66M | - | -1.85M | -1.55M | -866.00K | -908.00K | -1.29M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.85M | -1.55M | -866.00K | -908.00K | -1.29M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.81M | -1.55M | -877.00K | -928.00K | -1.17M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.94M | -11.13M | -1.71M | -1.80M | -14.90M | -4.93M | -5.67M | -9.19M | -3.16M | -3.48M | -5.60M | -4.45M | -5.22M | -6.19M | -4.82M | -5.22M | -5.16M | -7.84M | -3.56M | -4.69M | -1.17M | -10.55M | -4.10M | -3.85M | -8.18M | -4.97M | -4.59M | -5.05M | -4.45M | -3.82M | -3.77M | 825.00K | -5.81M | -2.59M | - | -1.81M | -1.55M | -877.00K | -928.00K | -1.17M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.36 | -1.45 | -1.22 | -1.04 | -1.03 | 0.23 | -1.59 | -0.71 | - | -0.50 | -0.42 | -0.24 | - | -0.32 |
| R&D Expense | 1.73M | 1.93M | 619.00K | 918.00K | 1.61M | 2.19M | 3.43M | 2.44M | 1.51M | 1.67M | 3.36M | 2.62M | 3.22M | 4.01M | 3.06M | 3.22M | 2.18M | 3.16M | 3.30M | 5.29M | 3.18M | 3.87M | 3.86M | 4.54M | 4.03M | 4.15M | 4.34M | 5.29M | 3.87M | 4.17M | 3.96M | 3.51M | 2.83M | 814.00K | - | 19.00K | 14.00K | 8.00K | - | 3.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2014 | Dec 2014 | Mar 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 352.00K | 0 | 1.20M | 835.00K | 335.00K | 153.00K | 7.91M | 12.63M | - | 6.07M | 7.30M | 7.81M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 25.02M | 22.04M | 14.95M | 5.17M |
| Operating Income | -3.12M | -9.08M | -6.71M | -23.02M | -24.87M | -17.48M | -20.40M | -20.69M | -9.86M | - | -18.95M | -14.74M | -7.14M | -5.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -17.40M | -13.27M | -6.71M | -5.17M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -18.84M | -14.12M | -9.56M | -5.16M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -3.12M | -24.14M | -6.69M | -26.17M | -27.84M | -18.06M | -20.56M | -20.60M | -19.31M | - | -18.84M | -14.12M | -9.56M | -5.16M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -5.46 | -3.87 | -2.62 | -1.41 |
| R&D Expense | 1.38M | 6.59M | 2.18M | 7.19M | 10.15M | 10.24M | 12.97M | 12.85M | 15.61M | 15.38M | 18.24M | 15.52M | 7.17M | 38.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2013 | Dec 2013 | Mar 2014 | Dec 2014 | Mar 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 15.58M | 1.55M | 10.68M | 44.87M | 16.66M | 15.98M | 14.72M | 36.10M | 38.09M | - | 40.95M | 33.96M | 9.94M | 4.14M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 38.15M | 20.84M | 9.92M | 4.13M |
| Cash & Equivalents | - | 1.43M | - | 451.00K | - | 18.90M | 4.18M | 3.55M | 2.56M | 23.44M | 31.66M | - | 35.63M | 19.17M | 9.52M | 4.09M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 67.00K | 1.30M | 928.00K | 0 | - |
| Total Liabilities | - | - | - | 44.77M | - | 12.27M | 7.90M | 5.84M | 2.88M | 25.08M | 14.96M | - | 9.84M | 15.96M | 996.00K | 329.00K |
| Current Liabilities | - | - | 947.00K | 43.46M | 635.00K | 3.60M | 4.65M | 5.84M | 2.88M | 17.20M | 8.18M | - | 5.02M | 3.91M | 929.00K | 329.00K |
| Long Term Debt | - | - | - | - | - | 5.69M | 3.22M | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 2.29M | 857.00K | 8.76M | 0 | - |
| Total Equity | 47.00K | -74.84M | 14.63M | -78.79M | 10.04M | 32.61M | 8.76M | 10.14M | 11.84M | 11.02M | 23.14M | - | 31.11M | 18.00M | 8.95M | 3.81M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 3.64M | 3.65M | 3.65M | 3.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2014 | Dec 2014 | Mar 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -14.48M | -16.76M | 3.23M | -12.48M | - | -19.36M | -15.98M | -10.72M | -5.43M |
| Investing Cash Flow | - | - | - | - | - | -74.00K | -19.00K | -58.00K | -281.00K | - | -86.00K | -676.00K | -398.00K | 0 |
| Financing Cash Flow | - | - | - | - | - | 13.92M | 15.79M | 17.70M | 20.98M | 43.48M | 1.23M | 53.00K | 0 | - |
| Capital Expenditure | -0 | -285.00K | -156.00K | -266.00K | -455.00K | -74.00K | -19.00K | -58.00K | -281.00K | -144.00K | -86.00K | -676.00K | -398.00K | - |
| Free Cash Flow | - | - | - | - | - | -14.55M | -16.78M | 3.17M | -12.76M | - | -19.44M | -16.66M | -11.11M | -5.43M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -18.21M | -16.61M | -11.11M | -5.43M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2014 | Dec 2014 | Mar 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -2,578.4% | - | -1,916.6% | -2,978.0% | -5,216.4% | -13,333.3% | -261.6% | -78.1% | - | -312.1% | -202.0% | -91.5% | - |
| Net Margin % | - | -6,859.1% | - | -2,178.8% | -3,334.5% | -5,389.9% | -13,439.9% | -260.4% | -152.8% | - | -310.3% | -193.5% | -122.5% | - |
| ROE % | -21.3% | 30.6% | -66.6% | -80.3% | -317.8% | -178.1% | -173.6% | -186.9% | -83.4% | - | -60.5% | -78.5% | -106.8% | -135.5% |
| ROCE % | -21.3% | 21.7% | -66.8% | -55.8% | -207.0% | -172.4% | -172.2% | -109.5% | -33.0% | - | -52.7% | -49.1% | -79.3% | -135.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PULM
Pulmatrix Announces First Quarter 2026 Financial Results
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with import…
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with an affiliate of Eos SENOLYTIX…
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases, today jointly announced a definit…
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
Wave’s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Elsewhere, Kodiak’s revived vision loss treatment succeeded in a second Phase 3 trial.
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and degrader antibody conjugate therapies,…
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with import…
PULM — Frequently Asked Questions
What is the current share price of PULM?
As of 2026-08-05 17:25 PDT, PULM trades at $1.65 on NASDAQ/NYSE. Its 52-week range is $1.19 to $5.48.
What is the market capitalisation of PULM?
PULM has a market capitalisation of $6.03M on NASDAQ/NYSE.
What is the P/E ratio of PULM?
PULM trades at a trailing price-to-earnings (P/E) ratio of -1.17. Its price-to-book (P/B) ratio is 1.58.
What is the return on equity (ROE) of PULM?
PULM has a return on equity (ROE) of -135.49%. Its return on capital employed (ROCE) is -135.67%.
Is PULM a good stock to buy?
This page provides a data-driven analysis of PULM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.